Targeting stromal cell sialylation reverses T cell-mediated immunosuppression in the tumor microenvironment

Immunosuppressive tumor microenvironments (TMEs) reduce the effectiveness of immune responses in can-cer. Mesenchymal stromal cells (MSCs), precursors to cancer-associated fibroblasts (CAFs), promote tumor progression by enhancing immune cell suppression in colorectal cancer (CRC). Hyper-sialylation of glycans promotes immune evasion in cancer through binding of sialic acids to their receptors, Siglecs, expressed on immune cells, which results in inhibition of effector functions. The role of sialylation in shaping MSC/ CAF immunosuppression in the TME is not well characterized. In this study, we show that tumor-conditioned stromal cells have increased sialyltransferase expression, x2,3/6-linked sialic acid, and Siglec ligands. Tumor -conditioned stromal cells and CAFs induce exhausted immunomodulatory CD8+ PD1+ and CD8+ Siglec-7+/ Siglec-9+ T cell phenotypes. In vivo, targeting stromal cell sialylation reverses stromal cell-mediated immuno-suppression, as shown by infiltration of CD25 and granzyme B-expressing CD8+T cells in the tumor and drain-ing lymph node. Targeting stromal cell sialylation may overcome immunosuppression in the CRC TME.

Automated summary

Immunosuppressive tumor microenvironments (TMEs) in cancer reduce immune responses, and mesenchymal stromal cells (MSCs) promote tumor progression through enhancing immune cell suppression in colorectal cancer (CRC). The hyper-sialylation of glycans promotes immune evasion by binding sialic acids to Siglecs receptors on immune cells, resulting in inhibition of their functions. However, the role of sialylation in MSC/CAF immunosuppression in the TME is not well characterized.